文献速递乳腺癌

加速表柔比星对比标准表柔比星后序贯环磷酰胺、甲氨蝶呤和氟尿嘧啶或卡培他滨作为乳腺癌辅助治疗的随机UK TACT2试验(CRUK/05/19):一项多中心、3期、开放标签、随机对照试验

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
PubMed 文献 · Lancet Oncol · 2017-06-07

UK TACT2试验采用2×2析因设计,纳入4391例可手术乳腺癌患者,比较加速表柔比星与标准表柔比星对无肿瘤复发时间(TTR)的影响,以及卡培他滨对比CMF的疗效与毒性。中位随访85.6个月,加速与标准表柔比星组TTR无显著差异(HR 0.94,95%CI 0.81-1.09;分层P=0.42)。卡培他滨对比CMF的TTR非劣效(HR 0.98,95%CI 0.85-1.14;非劣效性分层P=0.00092),且卡培他滨组生活质量更优。

要点

  • 加速表柔比星对比标准表柔比星未改善无肿瘤复发时间(HR 0.94,95%CI 0.81-1.09)。
  • 卡培他滨对比CMF在无肿瘤复发时间上达到非劣效(HR 0.98,95%CI 0.85-1.14)。
  • 卡培他滨组临床相关生活质量恶化比例低于CMF组(治疗结束时50% vs 58%,P=0.011)。

核心结论

  • 增加蒽环类化疗药物的剂量密度未带来获益。
  • 卡培他滨可替代CMF而不显著损失疗效,并改善生活质量。

研究设计与样本

  • 多中心、3期、开放标签、随机对照试验,采用2×2析因设计,于2005年12月16日至2008年12月5日从129个英国中心入组4391例患者(4371例女性,20例男性)。
  • 入组条件为年龄≥18岁、组织学确诊的淋巴结阳性或高危淋巴结阴性可手术乳腺癌、已完成完整切除、计划接受辅助化疗。
  • 随机分为4周期表柔比星100 mg/m2每3周一次(标准表柔比星)或每2周一次并于每周期第2天给予培非格司亭6 mg(加速表柔比星),随后序贯4周期4周方案的经典CMF(环磷酰胺600 mg/m2静脉第1、8天或100 mg/m2口服第1-14天;甲氨蝶呤40 mg/m2静脉第1、8天;氟尿嘧啶600 mg/m2静脉第1、8天)或4周期3周方案的卡培他滨2500 mg/m2(1250 mg/m2每日两次,第1-14天)。
  • 随机化按中心、受累淋巴结数(无 vs 1-3个 vs ≥4个)、年龄(≤50岁 vs >50岁)和计划内分泌治疗(是 vs 否)分层。
  • 主要终点为TTR,定义为从随机化至首次侵袭性复发或乳腺癌死亡的时间;标准 vs 加速表柔比星采用意向性分析,CMF vs 卡培他滨采用符合方案分析。

主要发现

  • 中位随访85.6个月(IQR 80.6-95.9),加速表柔比星组与标准表柔比星组无TTR事件的患者比例无显著差异(总体HR 0.94,95%CI 0.81-1.09;分层P=0.42)。
  • 5年时,标准表柔比星组85.9%(95%CI 84.3-87.3)无TTR事件,加速表柔比星组87.1%(95%CI 85.6-88.4)无TTR事件。
  • 符合方案分析纳入4358例患者,CMF组与卡培他滨组无TTR事件的患者比例无差异(HR 0.98,95%CI 0.85-1.14;非劣效性分层P=0.00092)。
  • 与基线相比,CMF组较卡培他滨组更多患者出现临床相关生活质量恶化:治疗结束时CMF组255/441例(58%)vs 卡培他滨组235/475例(50%),P=0.011;12个月时CMF组114/334例(34%)vs 卡培他滨组89/401例(22%),P<0.001;CMF组随时间生活质量更差(P<0.0001)。
  • 详细毒性和生活质量数据来自2115例(48%)接受治疗的患者;周期1-4中,标准表柔比星组1070例患者最常见≥3级不良事件为中性粒细胞减少(175例[16%])和疲乏(56例[5%]),加速表柔比星组1045例患者为疲乏(63例[6%])和感染(34例[3%]);周期5-8中,CMF组最常见≥3级不良事件为中性粒细胞减少(321例[31%])和疲乏(109例[11%]),卡培他滨组1044例患者为手足综合征(129例[12%])和腹泻(67例[6%])。

关键数值与推荐

  • 加速表柔比星对比标准表柔比星:无TTR事件比例无显著差异,总体HR 0.94(95%CI 0.81-1.09;分层P=0.42)。
  • 卡培他滨对比CMF:无TTR事件比例非劣效,HR 0.98(95%CI 0.85-1.14;非劣效性分层P=0.00092)。
  • 治疗结束时临床相关生活质量恶化:CMF组255/441例(58%)vs 卡培他滨组235/475例(50%),P=0.011。
  • 12个月时临床相关生活质量恶化:CMF组114/334例(34%)vs 卡培他滨组89/401例(22%),P<0.001。

临床怎么用

  • 作者认为增加蒽环类化疗药物的剂量密度未带来获益。
  • 作者认为卡培他滨可替代CMF而不显著损失疗效,并改善生活质量。

局限性

  • 详细毒性和生活质量数据仅来自2115例(48%)接受治疗的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to test two hypotheses: whether use of accelerated epirubicin would improve time to tumour recurrence (TTR); and whether use of oral capecitabine instead of cyclophosphamide would be non-inferior in terms of patients' outcomes and would improve toxicity, quality of life, or both. METHODS: In this multicentre, phase 3, randomised, controlled trial, we enrolled patients aged 18 years or older from 129 UK centres who had histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy. Patients were randomly assigned to receive four cycles of 100 mg/m2 epirubicin either every 3 weeks (standard epirubicin) or every 2 weeks with 6 mg pegfilgrastim on day 2 of each cycle (accelerated epirubicin), followed by four 4-week cycles of either classic cyclophosphamide, methotrexate, and fluorouracil (CMF; 600 mg/m2 cyclophosphamide intravenously on days 1 and 8 or 100 mg/m2 orally on days 1-14; 40 mg/m2 methotrexate intravenously on days 1 and 8; and 600 mg/m2 fluorouracil intravenously on days 1 and 8 of each cycle) or four 3-week cycles of 2500 mg/m2 capecitabine (1250 mg/m2 given twice daily on days 1-14 of each cycle). The randomisation schedule was computer generated in random permuted blocks, stratified by centre, number of nodes involved (none vs one to three vs four or more), age (≤50 years vs >50 years), and planned endocrine treatment (yes vs no). The primary endpoint was TTR, defined as time from randomisation to first invasive relapse or breast cancer death, with intention-to-treat analysis of standard versus accelerated epirubicin and per-protocol analysis of CMF versus capecitabine. This trial is registered with ISRCTN, number 68068041, and with ClinicalTrials.gov, number NCT00301925. FINDINGS: From Dec 16, 2005, to Dec 5, 2008, 4391 patients (4371 women and 20 men) were recruited. At a median follow-up of 85·6 months (IQR 80·6-95·9) no significant difference was seen in the proportions of patients free from TTR events between the accelerated and standard epirubicin groups (overall hazard ratio [HR] 0·94, 95% CI 0·81-1·09; stratified p=0·42). At 5 years, 85·9% (95% CI 84·3-87·3) of patients receiving standard epirubicin and 87·1% (85·6-88·4) of those receiving accelerated epirubicin were free from TTR events. 4358 patients were included in the per-protocol analysis, and no difference was seen in the proportions of patients free from TTR events between the CMF and capecitabine groups (HR 0·98, 95% CI 0·85-1.14; stratified p=0·00092 for non-inferiority). Compared with baseline, significantly more patients taking CMF than those taking capecitabine had clinically relevant worsening of quality of life at end of treatment (255 [58%] of 441 vs 235 [50%] of 475; p=0·011) and at 12 months (114 [34%] of 334 vs 89 [22%] of 401; p<0·001 at 12 months) and had worse quality of life over time (p<0·0001). Detailed toxicity and quality-of-life data were collected from 2115 (48%) of treated patients. The most common grade 3 or higher adverse events in cycles 1-4 were neutropenia (175 [16%]) and fatigue (56 [5%]) of the 1070 patients treated with standard epirubicin, and fatigue (63 [6%]) and infection (34 [3%]) of the 1045 patients treated with accelerated epirubicin. In cycles 5-8, the most common grade 3 or higher adverse events were neutropenia (321 [31%]) and fatigue (109 [11%]) in the patients treated with CMF, and hand-foot syndrome (129 [12%]) and diarrhoea (67 [6%]) in the 1044 patients treated with capcitabine. INTERPRETATION: We found no benefit from increasing the dose density of the anthracycline component of chemotherapy. However, capecitabine could be used in place of CMF without significant loss of efficacy and with improved quality of life. FUNDING: Cancer Research UK, Amgen, Pfizer, and Roche.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Cameron D, Morden JP, Canney P, et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2017. PMID: 28600210. doi:10.1016/S1470-2045(17)30404-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。